23andMe

23andMe
source
Name	23andMe
Foundation	0 2006
Founders	Linda Avey, Paul Cusenza, Anne Wojcicki
Location	South San Francisco, California, U.S.
Industry	Personal genomics, Biotechnology
Website	https://www.23andme.com

23andMe is a prominent direct-to-consumer genetics and biotechnology company based in South San Francisco, California. Founded in 2006, the company provides genetic testing kits that analyze an individual's DNA to deliver reports on ancestry, genetic traits, and health predispositions. Its services have played a significant role in popularizing personal genomics and have sparked widespread discussion regarding data privacy, bioethics, and the commercialization of genetic information.

History and founding

The company was established in 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki, with Wojcicki serving as its long-time Chief Executive Officer. Early financial backing came from prominent investors in Silicon Valley, including Google co-founder Sergey Brin, who was married to Wojcicki. The company's name references the 23 pairs of chromosomes in a typical human cell. A pivotal early moment was the launch of its first direct-to-consumer Personal Genome Service in 2007, which initially focused on ancestry and genealogy before expanding into health-related reports. The company navigated significant early regulatory scrutiny from the U.S. Food and Drug Administration regarding its health claims.

Products and services

Its primary product is a saliva collection kit used for DNA extraction and genotyping. Consumers receive online reports divided into several categories: Ancestry Composition, which estimates geographic origins and identifies DNA relatives; Health Predisposition reports, which indicate genetic risks for conditions like Alzheimer's disease or Parkinson's disease; and Carrier Status reports for autosomal recessive conditions such as cystic fibrosis. The company also offers a separate, physician-mediated service for pharmacogenetics reports and has developed a research platform leveraging its vast database for genetic research, often in collaboration with institutions like the National Institutes of Health and various pharmaceutical companies.

Technology and methodology

The service utilizes DNA microarray technology to perform genotyping, analyzing specific single-nucleotide polymorphisms across an individual's genome. This data is compared against a proprietary reference database built from thousands of genomic samples to generate ancestry estimates and identify genetic variants associated with specific traits or conditions. For health reports, the company focuses on well-established variants with documented associations in published scientific literature, such as the APOE gene variant linked to Alzheimer's disease. The underlying science and interpretation algorithms are developed by teams of population geneticists, statisticians, and bioinformaticians.

Privacy and data usage

The company's privacy policies and use of genetic data have been subjects of intense debate and scrutiny. Customers consent to having their de-identified genetic information used for internal research and shared with external partners, including academic researchers and biopharmaceutical firms like GlaxoSmithKline. This business model has raised concerns among bioethicists and regulators regarding informed consent, data security, and the potential for genetic discrimination. The company states it employs robust encryption and allows users to delete their data, but high-profile incidents, such as a 2023 data breach that exposed millions of profiles, have highlighted ongoing vulnerabilities.

Business and regulatory challenges

The company's path has been marked by significant regulatory hurdles, most notably a 2013 enforcement action by the U.S. Food and Drug Administration that forced it to temporarily halt marketing its health-related genetic tests. It resumed providing limited health reports in 2015 after gaining FDA authorization for specific tests, such as for Bloom syndrome. The company became a publicly-traded entity via a special-purpose acquisition company merger in 2021. It has faced multiple lawsuits related to its data privacy practices and the accuracy of its health reports, alongside increasing competition from rivals like Ancestry.com and MyHeritage.

Impact and cultural significance

The company has profoundly influenced public engagement with genetics, making genomic information accessible to millions outside traditional clinical settings. It has enabled significant genealogical discoveries, reunited families, and contributed to population-scale research projects, aiding studies on Parkinson's disease and lupus. Its model has fueled global conversations about identity, heritage, and the implications of widespread genetic testing, featured in media from The New York Times to The Atlantic. The database has also been used by law enforcement in cases like the Golden State Killer, raising complex questions about forensic genetics and ethical boundaries in the consumer genomics era.

Category:Biotechnology companies of the United States Category:Genetic testing companies Category:Companies based in San Mateo County, California